Richard L. Love, is a senior executive with 26 years of hands-on business leadership experience in the biosciences, coupled with 13 years of management experience in the petrochemical industry.  Mr. Love has led the start up of two biopharmaceutical businesses, Triton Biosciences Inc. and ILEX Oncology Inc. and served as CEO for both companies for periods of 8 years each. At Triton and ILEX, Dick led teams that were responsible for the clinical development of multiple important therapeutic products, four of which remain in use: Betaseron® for treatment of patients with multiple sclerosis; Fludara® and CAMPATH®, both for patients with chronic lymphocytic leukemia; and Clolar™ for treatment of patients with acute lymphocytic leukemia.  Triton was sold to Schering AG for proceeds in excess of $500 million (including earn-out) and ILEX was sold to Genzyme Corp for $1.04 billion.  Mr. Love has also served in senior executive positions at three non-profit research institutions, Cancer Therapy and Research Center, The San Antonio Technology Accelerator Initiative and the Translational Genomics Research Institute (TGen). Mr. Love currently serves as a director and founder of Systems Medicine, Inc. (Scottsdale), as a director of Parexel International (NASDAQ: PRXL) ImaRx Therapeutics (Tucson), Molecular Profiling Institute (Phoenix) and Medical Consulting Services (Scottsdale).  Mr. Love received an M.S. and B.S. in chemical engineering from Virginia Polytechnic Institute in 1967 and 1965, respectively.

Eric S. Tooker, JD., currently serves as the President and Chief Operating Officer of MCS Biotech, LLC, (“MCS”), which provides business, legal, administrative and support services to expert medical consultants.  Prior to MCS, Eric founded and served as President of Insights International, a provider of products and services focused on team-building, conflict resolution, hiring, and retention to for-profit and not-for-profit corporations. Mr. Tooker served as the Vice President and General Counsel for Central Newspapers, Inc (CNI) (NYSE: ECP) until the company was acquired by Gannett Co., Inc. in August 2000.  Mr. Tooker has extensive experience in advising executive business teams throughout his 15 years as an in-house counsel.  In that role with Conseco, Inc. (NYSE: CNO) he served as legal counsel and business adviser for a significant private equity portfolio and he lead mergers and acquisitions and associated bank financings.  Mr. Tooker earned a B.S. in Education from Miami University (Oxford, Ohio) and a J.D. from the University of Michigan Law School. 

Daniel D. Von Hoff, M.D., F.A.C.P., currently serves as Executive Vice President of TGen, Director of TGen’s Translational Drug Development Division.  He is also Clinical Professor of Medicine, Molecular and Cellular Biology and Pathology at the University of Arizona and has served as director of the Arizona Cancer Center.  He holds two major grants from the National Cancer Institute.  He is also Chief Scientific Officer of U.S. Oncology’s Research Network.  Dr. Von Hoff’s career is focused on the discovery and development of new anticancer agents.  He takes a unique approach toward preparing drug development strategies by envisioning the ultimate clinical trials required to gain FDA approval no matter how early the drug is in development.  Dr. Von Hoff is past president of the American Association for Cancer Research.  Dr. Von Hoff has been deeply involved in the development of numerous agents, including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, CAMPATH® chlofarabine, Abraxane and others. He is on the board of Genta, Inc. (Nasdaq: GNTA) and is a founder of Cylene.  He also serves as a consultant to many new start-up and established biotechnology companies.  Dr. Von Hoff has published more than 527 papers, 129 book chapters and 891 abstracts.

.